EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Optimizing the Injection Schema for Higher Doses of OnabotulinumtoxinA (BTX‐A) in the Office Setting: A Randomized Prospective Trial for Patients With Neurogenic Lower Urinary Tract Dysfunction and Idiopathic Overactive Bladder

Annie Chen, Julie Stewart, Ricardo R Gonzalez, Argyrios Stampas iD, Kathleen Kobashi, Rose Khavari iD

Neurourology and Urodynamics · 2025-11 · 44 (8) · 1537-1544

DOI: 10.1002/nau.70130 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Neurourology and Urodynamics, online erschienen am 20.08.2025. Verfasst von Annie Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Houston Methodist Hospital, Weill Cornell Medical College, Houston, Texas, USA. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Urinary Bladder, Overactive, Urinary Bladder, Neurogenic, Neuromuscular Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: This study was supported by Collaborating for the Advancement of Interdisciplinary Research in Benign Urology (CAIRIBU)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

OnabotulinumtoxinA (BTX‐A) decreases urge urinary incontinence (UUI) and improves quality of life for patients with idiopathic overactive bladder (IOAB) and neurogenic lower urinary tract dysfunction (NLUTD). Limited research exists optimizing injection techniques for higher doses (200‐ or 300‐units) of BTX‐A in the clinic setting. Optimization with less injections could improve satisfaction and willingness to repeat injections while maintaining effectiveness.

Methods

This is a prospective, single‐blinded, parallel randomized controlled trial of patients undergoing higher doses of BTX‐A for treatment of refractory IOAB or NLUTD in the office setting. Patients were randomized to either 5‐ or 20‐injections. The primary outcome was patients' willingness to repeat the procedure. Secondary outcomes included pain, symptomatology, and adverse events (AEs) assessments.

Results

For N = 78 participants ( N = 39 per arm), no difference was seen in patients' willingness to repeat the procedure between the 5‐ or 20‐injection groups before and after injection (Mean difference = 0.18, p = 0.57) or at 6–8 week follow‐up (Mean difference = 0.06, p = 0.83). There was a significant increase in immediate post‐procedural pain after 20 ( M = 3.39, SD 3.01) compared to five injections ( M = 0.57, SD = 2.07) (Mean difference = 2.83, p > 0.00002). N = 55/78 (71%) completed follow‐up. N = 16 experienced AEs ( N = 8/26 for 5‐injections, N = 7/29 for 20‐injections).

Conclusions

Despite a significant increase in pain for patients with NLUTD and IOAB receiving 20 injections compared to 5, patients in both groups were equally willing to repeat BTX‐A injections. There were no significant differences in AEs or secondary outcomes. This suggests decreasing the number of injections from 20 to 5 will improve pain scores when higher doses of BTX‐A are used in the office setting with affecting efficacy. Clinical Trial Number: NCT06059066.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type AUrinary Bladder, OveractiveUrinary Bladder, NeurogenicNeuromuscular AgentsAcetylcholine Release InhibitorsHumansFemaleMiddle AgedMaleProspective StudiesSingle-Blind MethodAgedTreatment OutcomeAdultPatient SatisfactionInjections

Stichwörter der Autor:innen

bladderbotoxbotulinum toxinsneurogenic bladderoveractiveoveractive bladderrandomized controlled trialtype aurinary bladderurinary incontinence

Substanzen

Botulinum Toxins, Type Aonabotulinum toxin ANeuromuscular AgentsAcetylcholine Release Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Houston Methodist Hospital, Weill Cornell Medical College, Houston, Texas, USA.
  • Physical Medicine and Rehabilitation, University of Texas, Houston, Texas, USA.
  • Houston Methodist Hospital, Weill Cornell Medical College, Houston, Texas, USA.

ORCID-Profile: Argyrios Stampas, Rose Khavari

Förderung

  • This study was supported by Collaborating for the Advancement of Interdisciplinary Research in Benign Urology (CAIRIBU).

Zitieren

APA

Chen, A., Stewart, J., Gonzalez, R. R., Stampas, A., Kobashi, K., & Khavari, R. (2025). Optimizing the Injection Schema for Higher Doses of OnabotulinumtoxinA (BTX‐A) in the Office Setting: A Randomized Prospective Trial for Patients With Neurogenic Lower Urinary Tract Dysfunction and Idiopathic Overactive Bladder. Neurourology and Urodynamics, 44(8), 1537-1544. https://doi.org/10.1002/nau.70130

Vancouver

Chen A, Stewart J, Gonzalez RR, Stampas A, Kobashi K, Khavari R. Optimizing the Injection Schema for Higher Doses of OnabotulinumtoxinA (BTX‐A) in the Office Setting: A Randomized Prospective Trial for Patients With Neurogenic Lower Urinary Tract Dysfunction and Idiopathic Overactive Bladder. Neurourology and Urodynamics. 2025;44(8):1537-1544. doi:10.1002/nau.70130

BibTeX
@article{Chen2025,
  author = {Chen, Annie and Stewart, Julie and Gonzalez, Ricardo R and Stampas, Argyrios and Kobashi, Kathleen and Khavari, Rose},
  title = {Optimizing the Injection Schema for Higher Doses of OnabotulinumtoxinA (BTX‐A) in the Office Setting: A Randomized Prospective Trial for Patients With Neurogenic Lower Urinary Tract Dysfunction and Idiopathic Overactive Bladder},
  journal = {Neurourology and Urodynamics},
  year = {2025},
  volume = {44},
  number = {8},
  pages = {1537--1544},
  doi = {10.1002/nau.70130}
}
Kostenlos starten →